Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mauro Schechter

Showing results (91-100 of 118) with videos related to

Pageof 12
Sort By:
Current HIV/AIDS Reports|August 1, 2016
Community-Based Interventions to Improve and Sustain Antiretroviral Therapy Adherence, Retention in HIV Care and Clinical Outcomes in Low- and Middle-Income Countries for Achieving the UNAIDS 90-90-90 TargetsJean B Nachega, Olatunji Adetokunboh, Olalekan A Uthman, et al.
BMC Infectious Diseases|June 30, 2012
Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settingsAlexandra Calmy, Eric Balestre, Fabrice Bonnet, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 9, 2007
Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries, , Martin W G Brinkhof, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 18, 2014
Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx StudyAlbert Liu, David V Glidden, Peter L Anderson, et al.
Science Translational Medicine|September 14, 2012
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with menPeter L Anderson, David V Glidden, Albert Liu, et al.
The New England Journal of Medicine|July 21, 2015
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection, Jens D Lundgren, Abdel G Babiker, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 19, 2007
Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120Farley Cleghorn, Jean W Pape, Mauro Schechter, et al.
The Lancet. Infectious Diseases|May 14, 2013
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trialsJoseph J Eron, David A Cooper, Roy T Steigbigel, et al.
Nature Communications|October 10, 2015
Immunological biomarkers predict HIV-1 viral rebound after treatment interruptionJacob Hurst, Matthias Hoffmann, Matthew Pace, et al.
JAMA|August 15, 2006
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panelScott M Hammer, Michael S Saag, Mauro Schechter, et al.
Pageof 12

Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
Current HIV/AIDS Reports|August 1, 2016
Community-Based Interventions to Improve and Sustain Antiretroviral Therapy Adherence, Retention in HIV Care and Clinical Outcomes in Low- and Middle-Income Countries for Achieving the UNAIDS 90-90-90 TargetsJean B Nachega, Olatunji Adetokunboh, Olalekan A Uthman, et al.
BMC Infectious Diseases|June 30, 2012
Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settingsAlexandra Calmy, Eric Balestre, Fabrice Bonnet, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 9, 2007
Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries, , Martin W G Brinkhof, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 18, 2014
Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx StudyAlbert Liu, David V Glidden, Peter L Anderson, et al.
Science Translational Medicine|September 14, 2012
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with menPeter L Anderson, David V Glidden, Albert Liu, et al.
The New England Journal of Medicine|July 21, 2015
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection, Jens D Lundgren, Abdel G Babiker, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 19, 2007
Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120Farley Cleghorn, Jean W Pape, Mauro Schechter, et al.
The Lancet. Infectious Diseases|May 14, 2013
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trialsJoseph J Eron, David A Cooper, Roy T Steigbigel, et al.
Nature Communications|October 10, 2015
Immunological biomarkers predict HIV-1 viral rebound after treatment interruptionJacob Hurst, Matthias Hoffmann, Matthew Pace, et al.
JAMA|August 15, 2006
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panelScott M Hammer, Michael S Saag, Mauro Schechter, et al.
Pageof 12